Multiple myeloma

Smith, Dean; Yong, Kwee

doi:10.1136/bmj.f3863

Cited by 71 publications

(66 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] It is characterized by clonal proliferation of malignant plasma cells in the bone marrow (BM) and often resulted in bone lesions, hypercalcemia, infections, anemia, and proteinemia. 4,5 Moreover, it has been recently reported that the incidence of MM was increasing over the last decade which makes MM a disease of considerable clinical, social, and economic impact.…”

Section: Introductionmentioning

confidence: 99%

EphA4 promotes cell proliferation and cell adhesion–mediated drug resistance via the AKT pathway in multiple myeloma

Ding

Shen

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Eph receptor A4 (EphA4), a member of the erythropoietin-producing hepatocellular (Eph) family, has been reported to upregulate in several tumors. However, the role of EphA4 in multiple myeloma has not been clarified yet. In this study, we found that EphA4 promoted proliferation of multiple myeloma cells via the regulation of cell cycle. Besides, EphA4 was closely related to cell adhesion of multiple myeloma cells and promoted cell adhesion–mediated drug resistance by enhancing the phosphorylation levels of Akt (p-AKT) expression in multiple myeloma. More interestingly, we discovered that EphA4 can interact with cyclin-dependent kinase 5 (CDK5) and regulate its expression in multiple myeloma. CDK5 has been reported to be overexpressed in multiple myeloma which mediated bortezomib resistance and also participated in AKT pathway. And we have also proved the fact. So, we supposed that EphA4 interacted with CDK5 and promoted its expression which in turn enhanced p-AKT expression and promoted cell adhesion–mediated drug resistance in multiple myeloma. Therefore, this study clarifies the molecular mechanism of cell adhesion–mediated drug resistance and may be useful in identifying potential target for treatment of multiple myeloma.

show abstract

Section: Introductionmentioning

confidence: 99%

EphA4 promotes cell proliferation and cell adhesion–mediated drug resistance via the AKT pathway in multiple myeloma

Ding

Shen

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

show abstract

“…다발성 골수종 환자의 삶의 질 이나 장기부전 증상이 나타나면 즉시 치료를 시작한다 [1,3]. 이 전에는 다발성 골수종의 치료목적을 완치보다는 질환으로 인 한 증상을 완화하고 생존기간을 연장하는 것에 중점을 두고 [3,10,11] 멜팔란과 프레드니솔론으로 치료하였으나 최근에는 탈리도마이드나 레날리도마이드, 보르테조밉과 같은 새로운 치료제가 도입되면서 치료결과가 향상되었다 [1,5].…”

unclassified

“…이 전에는 다발성 골수종의 치료목적을 완치보다는 질환으로 인 한 증상을 완화하고 생존기간을 연장하는 것에 중점을 두고 [3,10,11] 멜팔란과 프레드니솔론으로 치료하였으나 최근에는 탈리도마이드나 레날리도마이드, 보르테조밉과 같은 새로운 치료제가 도입되면서 치료결과가 향상되었다 [1,5]. 특히 65세 이하의 환자에게 관해유지요법 이후 자가 조혈모세포이식 시 행을 표준치료로 확립하면서 생존율뿐만 아니라 무병 생존율 도 증가하였다 [7,11,12].…”

unclassified

Quality of Life in Patients with Multiple Myeloma

Ban

Yoon

et al. 2016

Korean J Adult Nurs

View full text Add to dashboard Cite

Purpose:The purpose of this study was to identify the quality of life reported by patients with multiple myeloma and secondly to identify the factors that impact the quality of life (QoL). Methods: 189 patients with multiple myeloma completed survey questionnaires. Quality of life was evaluated using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C) 30 and Multiple Myeloma (MY) 20. The data were analyzed using the t-test, ANOVA, Kruskal-Wallis test, Duncan test and the Mann-Whitney test. Results: The mean score for each subscale of EORTC QLQ-C30 was 53.35 for global health status, 73.37 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of EORTC QLQ-MY20 was 60.49 for future perspective, 59.78 for body image, 20.25 for disease symptom and 24.99 for side effect of treatment. Quality of life was reported to be significantly lower among females, unemployed, dependence on a sibling for financial support for treatment, a diagnosis of anemia, having treatment, high score on Eastern Coorperative Oncology Group and high grade peripheral neuropathy. Conclusion: The results of the survey can identify characteristics impacting the QoL of patients with multiple myeloma. Developing appropriate educational strategies and nursing interventions would enhance their QoL.

show abstract

“…Multiple myeloma (MM), the second most common blood cancer, continues to be incurable, despite treatment advancement [1]. The communication between cancer cells and bone marrow niche drive the disease phenotypes and treatment response.…”

Section: Introductionmentioning

confidence: 99%